1. Home
  2. SONN vs AIIOW Comparison

SONN vs AIIOW Comparison

Compare SONN & AIIOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SONN
  • AIIOW
  • Stock Information
  • Founded
  • SONN N/A
  • AIIOW N/A
  • Country
  • SONN United States
  • AIIOW United Arab Emirates
  • Employees
  • SONN N/A
  • AIIOW N/A
  • Industry
  • SONN Biotechnology: Pharmaceutical Preparations
  • AIIOW Auto Manufacturing
  • Sector
  • SONN Health Care
  • AIIOW Industrials
  • Exchange
  • SONN Nasdaq
  • AIIOW Nasdaq
  • Market Cap
  • SONN 21.4M
  • AIIOW 19.0M
  • IPO Year
  • SONN N/A
  • AIIOW N/A
  • Fundamental
  • Price
  • SONN $2.85
  • AIIOW $0.06
  • Analyst Decision
  • SONN Strong Buy
  • AIIOW
  • Analyst Count
  • SONN 1
  • AIIOW 0
  • Target Price
  • SONN $20.00
  • AIIOW N/A
  • AVG Volume (30 Days)
  • SONN 563.6K
  • AIIOW N/A
  • Earning Date
  • SONN 08-13-2025
  • AIIOW N/A
  • Dividend Yield
  • SONN N/A
  • AIIOW N/A
  • EPS Growth
  • SONN N/A
  • AIIOW N/A
  • EPS
  • SONN N/A
  • AIIOW N/A
  • Revenue
  • SONN $1,000,000.00
  • AIIOW N/A
  • Revenue This Year
  • SONN $5,376.22
  • AIIOW N/A
  • Revenue Next Year
  • SONN N/A
  • AIIOW N/A
  • P/E Ratio
  • SONN N/A
  • AIIOW N/A
  • Revenue Growth
  • SONN 1689.52
  • AIIOW N/A
  • 52 Week Low
  • SONN $1.08
  • AIIOW N/A
  • 52 Week High
  • SONN $19.30
  • AIIOW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SONN 39.92
  • AIIOW N/A
  • Support Level
  • SONN $3.02
  • AIIOW N/A
  • Resistance Level
  • SONN $3.80
  • AIIOW N/A
  • Average True Range (ATR)
  • SONN 0.31
  • AIIOW 0.00
  • MACD
  • SONN -0.04
  • AIIOW 0.00
  • Stochastic Oscillator
  • SONN 10.26
  • AIIOW 0.00

About SONN Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Share on Social Networks: